Latest Ventricular assist device Stories
PLEASANTON, Calif., March 18, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies to save, support, and restore failing hearts, announced today that it has successfully completed the first human use of HeartMate PHP (Percutaneous Heart Pump). The first PHP patient was supported for over 60 minutes during a high-risk percutaneous coronary intervention (HR PCI). The patient was hemodynamically stable...
PLEASANTON, Calif., March 11, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Barclays Global Healthcare Conference on Thursday, March 14. Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, beginning at 8:00 a.m., Eastern Daylight Time (5:00 a.m., Pacific Daylight...
FRAMINGHAM, Mass., and SYDNEY, March 6, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Barclays Capital 2013 Global Healthcare Conference at 11:15 a.m. EDT on Tuesday, March 12, 2013. The conference is being held March 12-14, 2013 at the...
FRAMINGHAM, Mass. and SYDNEY, Feb. 28, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Raymond James 34(th) Annual Institutional Investors Conference at 1:05 p.m. Eastern Standard Time on Tuesday, March 5, 2013. The conference is being...
SAN DIEGO, Feb. 20, 2013 /PRNewswire/ -- Ventrix, Inc. announced today that its VentriGel((TM)) cardiac repair scaffold safely and effectively mitigated left ventricular remodeling and improved cardiac function in pigs after myocardial infarction, or heart attack. The findings, made during pre-clinical studies, were published today in the journal Science Translational Medicine. Based on these and other results, Ventrix will initiate a first-in-man clinical trial for VentriGel later...
FRAMINGHAM, Mass. and SYDNEY, Feb. 19, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended December 31, 2012, at 8:30 a.m. U.S. Eastern Standard Time on Wednesday, February 27, 2013. The Company plans to release the financial results prior to the conference call. The conference call with management will discuss the Company's financial results, highlights from the fourth...
During a recent webinar hosted by AllMed Healthcare Management, Dr. Dale Mueller, a board-certified thoracic and cardiac surgeon, discussed the use of left ventricular assist devices (LVADs) for mechanical circulatory support and their potential complications. Portland, OR (PRWEB) February 18, 2013 During a recent webinar hosted by AllMed Healthcare Management, Dr. Dale Mueller, a board-certified thoracic and cardiac surgeon, discussed the use of left ventricular assist devices (LVADs)...
PLEASANTON, Calif., Feb. 11, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Leerink Swann 2013 Global Healthcare Conference on Thursday, February 14. Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, beginning at 9:00 a.m., Eastern Standard Time (6:00 a.m., Pacific...
FRAMINGHAM, Mass. and SYDNEY, Feb. 8, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Leerink Swann Global Healthcare Conference at 8:30 a.m. Eastern Standard Time on Wednesday, February 13, 2013. The conference is being held February...
PLEASANTON, Calif., Feb. 5, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today reported its financial results for the fourth quarter of 2012. "Thoratec had an impressive year in 2012, with sales growth of 16 percent driven by our HeartMate II® and CentriMag® product lines, highlighting our leadership positions in chronic and acute mechanical...
Latest Ventricular assist device Reference Libraries
The artificial heart, a mechanical heart replacement, is typically used in order to bridge the time to heart transplant or to replace the heart in case a transplant is impossible. Often ventricular assist devices are confused with mechanical hearts because the assist the heart through pumps. They are also different from a cardiopulmonary bypass machine which is an external device used to provide the function of the heart and lungs. CPBs are usually only used for a few hours at a time,...
